For the safety of our patients and staff, we have updated our visitor policy, effective December 27. This includes important information about COVID-19 vaccination or testing for some visitors. Read the latest information for visitors.
The Tumor Suppressor PP2A as a Therapeutic Target for Eradication of TKI-resistant Ph+ Leukemic Stem Cells
Host: Ross Levine, MD
Tea will be served at 4:15 pm.
This program is for the research community.
Date & Time(s)
Memorial Sloan Kettering Cancer Center
Zuckerman Research Center
417 East 68th Street
Room ZRC 105
New York, NY 10065
Human Oncology and Pathogenesis Program
Danilo Perrotti, MD, PhD
Molecular Virology, Immunnology, and Genetics
Ohio State University